This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SGEN Seagen (SGEN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisFDA EventsInsider TradesTrendsBuy This Stock About Seagen Stock (NASDAQ:SGEN) Get Seagen alerts:Sign Up Key Stats Today's Range$228.74▼$228.7450-Day Range$228.74▼$228.7452-Week Range$123.77▼$228.96VolumeN/AAverage Volume1.48 million shsMarket Capitalization$42.93 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc. Read More Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SGEN Stock News HeadlinesNurix Therapeutics appoints Dansey to board of directorsNovember 10, 2025 | msn.comPfizer raises guidance as COVID franchise drives Q3 beatOctober 30, 2024 | seekingalpha.comUnder $1 while the market panicsPresident Trump just called on the Senate to pass the CLARITY Act “in honor” of the late Senator Lindsey Graham, whom Trump described as a major supporter of the legislation. Whether you currently own crypto or only hold stocks, this legislation deserves your attention. The CLARITY Act is designed to establish clearer rules for digital assets—potentially giving banks, asset managers and other financial institutions a more defined path into blockchain-based markets. That could accelerate one of the biggest shifts already unfolding in finance: The movement of securities, payments and other real-world assets onto blockchain infrastructure.July 16 at 1:00 AM | Crypto 101 Media (Ad)Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are UnimpressedOctober 30, 2024 | seekingalpha.comFranklin Biotechnology Discovery COctober 5, 2024 | morningstar.comMPfizer: Turning The Corner (Rating Upgrade)May 27, 2024 | seekingalpha.comTwo Brothers, a Big Biotech Bet and an $8 Billion PayoutApril 13, 2024 | wsj.comRon Baron Portfolio Magic: Building Your Financial FutureMarch 20, 2024 | msn.comSee More Headlines SGEN Stock Analysis - Frequently Asked Questions How were Seagen's earnings last quarter? Seagen Inc. (NASDAQ:SGEN) released its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.33. Seagen's quarterly revenue was up 27.1% on a year-over-year basis. Does Seagen have any subsidiaries? Seagen subsidiaries include these companies: Cascadian Therapeutics. What other stocks do shareholders of Seagen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seagen investors own include NVIDIA (NVDA), Meta Platforms (META), Intel (INTC), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE) and Qualcomm (QCOM). Company Calendar Last Earnings11/01/2023Today7/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SGEN CIK1060736 Webwww.seattlegenetics.com Phone(425) 527-4000Fax425-527-4001Employees3,256Year Founded1998Profitability EPS (Trailing Twelve Months)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$610.31 million Net Margins-32.61% Pretax Margin-32.12% Return on Equity-28.06% Return on Assets-20.92% Debt Debt-to-Equity RatioN/A Current Ratio2.67 Quick Ratio2.12 Sales & Book Value Annual Sales$2.30 billion Price / Sales18.66 Cash FlowN/A Price / Cash FlowN/A Book Value$15.10 per share Price / Book15.15Miscellaneous Outstanding Shares187,698,000Free Float139,084,000Market Cap$42.93 billion OptionableNo Data Beta0.32 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:SGEN) was last updated on 7/16/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe window is closingWe printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline b...American Alternative | SponsoredUnder $1 while the market panicsPresident Trump just called on the Senate to pass the CLARITY Act “in honor” of the late Senator Lindsey Graha...Crypto 101 Media | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThis Is How Financial Freedom Dies—And Most People Never See It ComingWhile the trade war grabs headlines, the Department of Justice has quietly argued in court that cash may not b...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seagen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.